Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Parkinson's Disease Psychosis: later-stage trial registry
2 of 4 indexed Parkinson's Disease Psychosis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Parkinson's Disease Psychosis: 4 US clinical trials tracked, 2 recruiting.
Parkinson's Disease Psychosis is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is ACADIA Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition parkinsons-disease-psychosis
OPEN 2 | RECR 50% | LATE 4 | EARLY 0 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Parkinson's Disease Psychosis lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Parkinson's Disease Psychosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Parkinson's Disease Psychosis is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
VA Office of Research and Development
NCT04373317
Comparing Antipsychotic Medications in LBD Over Time
The University of Texas Health Science Center at San Antonio
NCT05590637
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
ACADIA Pharmaceuticals
NCT00477672
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
ACADIA Pharmaceuticals
NCT01174004
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Parkinson's Disease Psychosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Parkinson's Disease Psychosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Parkinson's Disease Psychosis page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Parkinson's Disease Psychosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ACADIA Pharmaceuticals sponsors the most Parkinson's Disease Psychosis trials on record, review their full trial history before evaluating a specific study. See ACADIA Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinson's Disease Psychosis condition card totals 4 registered trials; most-linked intervention Pimavanserin; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.